Deltex Medical Group announces Tim Irish and Mark Wippell to Board as Non-Executive Directors

– UK – Deltex Medical Group plc, the global leader in oesophageal Doppler monitoring, is pleased to announce the proposed appointment of two Non-Executive Directors, Tim Irish and Mark Wippell, shortly after the Company’s Annual General Meeting to be held on 7 May 2014.

Timothy Norris Irish, aged 49, has almost 30 years’ experience in the healthcare industry, both in the UK and internationally. Having been global head of marketing and strategy for Phillips Medical and a Vice President for GE Medical in Europe, he has substantial experience in marketing medical products in a number of Deltex’s key existing markets. More recently Tim was Chairman of the Dutch Company, BMEYE BV, which developed signal acquisition modalities and was successfully sold to Edwards Life Sciences in the USA. Edwards is a major player in the Inter Operative Fluid Management market. For the last eight years Tim has held numerous Board roles, primarily for European Venture Capital backed technology businesses.

Mark Alexander Wippell, aged 55, is a Partner with Allen & Overy LLP and has significant experience advising international companies on their strategic transactions, including advising at Board level.  His experience includes public and private M&A, business reorganisations, complex joint ventures and demergers.  Mark is qualified as a lawyer in both the UK and the USand his wide commercial experience will be particularly helpful to the Company as it expands its presence in North America.

Dr Ed Snape, Vice-Chairman and Professor Sir Duncan Nichol have both announced their intention to retire from the Board as Non-Executive Directors, effective as of the close of the AGM on 7 May and after publication of the Interim Results Statement in September 2014, respectively.

Nigel Keen, Deltex Medical’s Chairman, commented:”I am pleased to welcome Tim and Mark to the Board, they offer wealth of experience that will aid the further development of Deltex and its growing market focus, particularly in the USA.

“The Board would like to thank Ed and Duncan for their significant contribution over the years. We wish them both well in their retirement from Deltex Medical.”

About Deltex Medical

Deltex Medical manufactures and markets CardioQ-ODMÔ Oesophageal Doppler Monitoring (‘ODM’) systems.ODM is the only therapy to measure blood flow in the central circulation in real time. Minimally invasive, easy to set up and quick to focus, the technology generates a low-frequency ultrasound signal, which is highly sensitive to changes in flow and measures them immediately. Randomised, controlled trials using Doppler have demonstrated that early fluid management intervention will reduce post-operative complications, reduce intensive care admissions, and reduce the length of hospital stay.

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Comments are closed.